Here are three takeaways:
1. NuVasive will launch the following products:
• AttraX Putty Biotextured Bone Graft, a next-generation, synthetic biologic product indicated for use as an autograft extender in posterior lateral spine applications.
• Reline Modular System, which is designed to improve visualization and access to the intervertebral disc for fusion work in TLIF and PLIF procedures.
• Reline Power, which expedites screw placement with its integrated power delivery system, ergonomically designed for surgeons.
• MAS TLIF 2, which is the next-generation of NuVasive’s minimally-invasive, pedicle-based approach.
• Monolith Corpectomy System, a fully modular, imaging-friendly PEEK implant indicated for use T1-L5 with supplemental fixation.
2. Additionally, the company will conduct demonstrations of its Integrated Global Alignment system.
3. NuVasive released its first quarter financial report on April 27. The company reported total revenue of $215.1 million in first quarter 2016, an 11.8 percent increase from the $192.4 million reported for the first quarter of 2015.
More articles on devices:
Where global spine market leaders are headed: 7 key notes on Medtronic, DePuy Synthes, Stryker & more
Gabelli reiterates ‘buy’ rating for LDR stock: 4 points
Integra LifeSciences, AlloSource sign agreement for acellular dermal matrices: 4 takeaways
